D-Pharm Ltd.
Records under this name other than patents D-Pharm Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,799,831 | Lipophilic Diesters of Chelating Agent for Inhibition of Enzyme Activity Term ended Term ended Jul 24, 2025 · High confidence | Term ended | Term ended Jul 24, 2025 | High confidence |
| US 7,745,426 | Compositions and Methods for Reducing the Risk of Epileptic Occurrence And/Or for Treatment of Seizure Disorders Formerly held Lapsed on the fee record Ended Jun 29, 2022 · High confidence | Lapsed on the fee record | Ended Jun 29, 2022 | High confidence |
| US 7,186,703 | Derivatives of Branched-Chain Lipophilic Molecules and Uses Thereof Term ended Term ended May 23, 2022 · High confidence | Term ended | Term ended May 23, 2022 | High confidence |
| US 8,507,436 | Peptides derived from plasminogen activator inhibitor-1 and uses thereof Lapsed on the fee record Ended Aug 13, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 13, 2021 | From the USPTO record |
| US 7,173,018 | Phospholipid Derivatives of Non-Steroidal Anti-Inflammatory Drugs Term ended Term ended Jul 16, 2020 · High confidence | Term ended | Term ended Jul 16, 2020 | High confidence |
| US 6,313,106 | Phospholipid derivatives of valproic acid and mixtures thereof Term ended Term ended Jul 12, 2020 · From the USPTO record | Term ended | Term ended Jul 12, 2020 | From the USPTO record |
| US 6,458,837 | Lipophilic diesters of chelating agents Term ended Term ended Mar 27, 2020 · From the USPTO record | Term ended | Term ended Mar 27, 2020 | From the USPTO record |
| US 6,166,089 | Prodrugs with enhanced penetration into cells Term ended Term ended Oct 28, 2019 · From the USPTO record | Term ended | Term ended Oct 28, 2019 | From the USPTO record |
| US 7,271,143 | Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy Lapsed on the fee record Ended Sep 18, 2019 · From the USPTO record | Lapsed on the fee record | Ended Sep 18, 2019 | From the USPTO record |
| US 6,136,796 | Prodrugs with enhanced penetration into cells Term ended Term ended Mar 16, 2019 · From the USPTO record | Term ended | Term ended Mar 16, 2019 | From the USPTO record |